MAIA Biotechnology Ev To Operating Cash Flow Over Time
| MAIA Stock | USD 2.09 0.09 4.50% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out MAIA Biotechnology Performance and MAIA Biotechnology Correlation. MAIA |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MAIA Biotechnology. If investors know MAIA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MAIA Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.34) | Return On Assets (1.07) | Return On Equity (5.60) |
The market value of MAIA Biotechnology is measured differently than its book value, which is the value of MAIA that is recorded on the company's balance sheet. Investors also form their own opinion of MAIA Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is MAIA Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MAIA Biotechnology's market value can be influenced by many factors that don't directly affect MAIA Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between MAIA Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if MAIA Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MAIA Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Ev To Operating Cash Flow Analysis
Compare MAIA Biotechnology and related stocks such as Lineage Cell Therapeutics, Armata Pharmaceuticals, and Frequency Therapeutics Ev To Operating Cash Flow Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LCTX | (12.7948) | (18.4766) | (7.6313) | (6.4292) | (5.6254) | (6.5034) | (7.8723) | (6.9082) | (3.049) | (3.9188) | (11.8865) | (14.8589) | 181 | (5.451) | (5.72) |
| ARMP | (2.8 K) | (2.6143) | (2.6143) | (4.0608) | (2.5311) | (1.2439) | 0.0547 | (0.1435) | 0.4503 | (1.4291) | (2.8735) | (6.778) | (2.3548) | (4.7178) | (4.95) |
| PRTG | (15.658) | (35.1998) | (158) | (200) | (177) | (97.7352) | (731) | (393) | (1.1 K) | (537) | (1.5 K) | (250) | (81.6375) | (15.3868) | (16.16) |
| LRMR | (29.8718) | (29.8718) | (29.8718) | (29.8718) | (29.8718) | (2.3355) | (1.1168) | (2.4202) | (2.5412) | (5.3665) | (4.5685) | (2.8763) | (3.0824) | (5.3363) | (5.6) |
| LYRA | (13.9183) | (13.9183) | (13.9183) | (13.9183) | (13.9183) | (13.9183) | (13.9183) | (13.9183) | (13.9183) | (16.9695) | (1.219) | (0.4774) | (1.4891) | (4.1941) | (4.4) |
| GNLX | (22.5369) | (22.5369) | (22.5369) | (22.5369) | (22.5369) | (22.5369) | (22.5369) | (22.5369) | (22.5369) | (22.5369) | (22.1991) | (25.2165) | (49.5547) | (16.5403) | (17.37) |
| DYAI | (243) | 164 | 164 | 9.5267 | (6.0796) | 7.9678 | (8.9082) | (13.3136) | (11.3261) | (23.3543) | (19.3417) | (9.7615) | (3.5991) | (5.9446) | (5.65) |
| CING | (5.4547) | (5.4547) | (5.4547) | (5.4547) | (5.4547) | (5.4547) | (5.4547) | (5.4547) | (5.4547) | (5.4547) | (7.5135) | (1.4955) | (0.7227) | (0.6656) | (0.7) |
| MNPR | (2.2 K) | (2.2 K) | (2.2 K) | (2.2 K) | (2.2 K) | (2.2 K) | (1.2 K) | (522) | (476) | (287) | (68.3326) | (24.5818) | (19.718) | (2.2147) | (2.33) |
| CSBR | (158) | (5.0912) | (1.9378) | (16.0079) | (5.643) | (4.8008) | (8.7563) | (38.2012) | 53.5703 | 29.9097 | (86.7908) | 15.6708 | 16.2561 | (11.4906) | (12.07) |
| LUMO | (1.2426) | 2.1307 | (0.7713) | (0.2926) | (0.6105) | 3.3075 | 1.4876 | 2.7006 | 3.0141 | 2.9449 | (6.2478) | 1.2309 | 0.9595 | 0.2763 | 0.4 |
| NAUT | (0.3308) | (0.3308) | (0.3308) | (0.3308) | (0.3308) | (0.3308) | (0.3308) | (0.3308) | (0.3308) | (36.1667) | (20.9513) | (7.1842) | (3.0578) | (7.5175) | (7.89) |
MAIA Biotechnology and related stocks such as Lineage Cell Therapeutics, Armata Pharmaceuticals, and Frequency Therapeutics Ev To Operating Cash Flow description
A valuation metric comparing the company's enterprise value to its operating cash flow, indicating how many dollars of EV are generated for each dollar of operating cash flows.My Equities
My Current Equities and Potential Positions
| MAIA Biotechnology | MAIA |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Illinois; U.S.A |
| Exchange | NYSE MKT Exchange |
USD 2.09
Check out MAIA Biotechnology Performance and MAIA Biotechnology Correlation. For information on how to trade MAIA Stock refer to our How to Trade MAIA Stock guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
MAIA Biotechnology technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.